BioCentury
ARTICLE | Clinical News

Intuniv guanfacine extended release regulatory update

August 3, 2009 7:00 AM UTC

FDA issued a complete response letter for Intuniv guanfacine extended release to treat ADHD in children and adolescents ages 6-17. Shire said it was unable to agree with the agency on product labeling...